AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03193658
Drug: I.V drug based multimodal approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A base low dose opioid of 5mg morphine I.V every 8 hours. Rescue analgesia will be given to the patient if reported a VAS equal or more than 4 in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours
Trial: NCT01921985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
Trial: NCT02560324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04182568
Drug: nab-paclitaxel followed by anthracycline and cyclophosphamide
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide
Trial: NCT04182568
Drug: Docetaxel followed by anthracycline and cyclophosphamide
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide
Trial: NCT00501059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken daily
Trial: NCT00270231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule.
Trial: NCT01147757
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During surgery, 3 different dose of remifentanil or placebo was infused.
Trial: NCT02710669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00511316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 20 mg daily for 6 months
Trial: NCT00091637
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bolus infusion over a 10 minute period once
Trial: NCT01746238
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks
Trial: NCT03433313
Drug: EG12014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG12014 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
Trial: NCT00069784
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo gelatin capsules (containing olive oil) for oral administration
Trial: NCT02512679
Drug: Cyclophosphamide Dose Level 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.
Trial: NCT02512679
Drug: Cyclophosphamide Dose Level 2
RxNorm normalized name: cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;
Trial: NCT02512679
Drug: Cyclophosphamide Dose Level 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 3 will be 35mg/kg as a one-time dose.
Trial: NCT02512679
Drug: Cyclophosphamide Dose Level 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 4 will be no cytoxan.
Trial: NCT02063100
Drug: Shenyankangfu tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
Trial: NCT03660475
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ophthalmic solution
Trial: NCT02535130
Drug: amikacine nebulization
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00432276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets.
Trial: NCT00297115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00959062
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation visually identical to clonidine.
Trial: NCT02334553
Drug: S1226(8%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
Trial: NCT02334553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
Trial: NCT01528943
Drug: Prostacycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min
Trial: NCT01528943
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same volume as the group that are allocated to prostacycline
Trial: NCT02755064
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Phase 1 of the study, during the second visit, saline was given as an initial bolus over 10 min immediately before the meal. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
Trial: NCT02755064
Drug: [13C]-Spirulina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
Trial: NCT02755064
Drug: Placebo Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days.
Trial: NCT03140956
Drug: Levodopa, carbidopa, ODM-104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover design. Study treatments will be administered in randomized order 4 times a day.
Trial: NCT01128218
Drug: Tumor fluorescence
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2
Trial: NCT04030962
Drug: AGN-242428
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic solution administered as a topical eye drop
Trial: NCT01984489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02590874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
Trial: NCT01523184
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the placebo capsule
Trial: NCT01523184
Drug: YKP10811 Drug Product Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug product, YKP10811, 10 mg under investigation
Trial: NCT01523184
Drug: YKP10811 Drug Product Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug product, YKP10811, 20 mg under investigation
Trial: NCT01523184
Drug: YKP10811 Drug Product Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug product, YKP10811, 30 mg under investigation
Trial: NCT03962296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets lacked Vitis vinifera extract or calcium dobesilate, but their appearance was identical to those of the study group tablets.
Trial: NCT02000830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered by IM injection
Trial: NCT02737228
Drug: CG200745 PPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CG200745 PPA IV every week three times per cycle (4 weeks)
Trial: NCT02277158
Drug: Chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 CCRT
Trial: NCT01966419
Drug: ornithine phenylacetate
RxNorm normalized name: phenylacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornithine phenylacetate for continuous IV infusion at dose levels predicated on level of hepatic decompensation
Trial: NCT04500496
Drug: dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
Trial: NCT01966419
Drug: placebo intravenous infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for continuous IV infusion that is visually identical to the experimental product
Trial: NCT02962323
Drug: Torrent's Rosuvastatin Calcium Tablets 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, crossover
Trial: NCT02962323
Drug: Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, crossover
Trial: NCT01264380
Drug: RO5185426
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose, fasted
Trial: NCT01264380
Drug: RO5185426
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose, with high fat meal
Trial: NCT01264380
Drug: RO5185426
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration, orally twice daily
Trial: NCT00240955
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02563002
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen consists of oxaliplatin 85 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
Trial: NCT02563002
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen consists of irinotecan 180 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-FU 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
Trial: NCT03240224
Drug: Life information rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Trial: NCT02466646
Drug: Klorhex® Gel, rinse and spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
Trial: NCT02768610
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02401464
Drug: TAK-536 Dry Syrup Formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-536 dry syrup formulation
Trial: NCT02401464
Drug: TAK-536 Ganule Formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-536 granule formulation
Trial: NCT00886028
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
Trial: NCT03270514
Drug: Exparel Injectable Product
RxNorm normalized name: Exparel Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
Trial: NCT00624559
Drug: celecoxib (Celebrex)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
Trial: NCT03620422
Drug: Salbutamol 5mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
Trial: NCT02801669
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally administered once daily.
Trial: NCT01444365
Drug: ABT-652 NSAID
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
Trial: NCT02295566
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Not required
Trial: NCT01444365
Drug: Placebo NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 2 placebo capsules twice daily NSAID- as prescribed
Trial: NCT01363128
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01363128
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01363128
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00680134
Drug: AN2690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
Trial: NCT00016042
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02271399
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
Trial: NCT04492150
Drug: Dextrose 5%/Nacl 0.3% Inj_#3
RxNorm normalized name: DEXTROSE 5%/NACL 0.3% INJ_#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL/hour of dextrose 5% intravenous drip
Trial: NCT00003305
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01555190
Drug: myo-inositol 1500 gr
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01555190
Drug: myo-inositol 2000 gr + folic acid 200 mcg
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04492319
Drug: Control Test
RxNorm normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spermatic cord block by 19 ml Levobupivacaine 0.5% plus 1 ml 0.9 normal saline in each side
Trial: NCT05691764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo
Trial: NCT00894790
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
Trial: NCT00894790
Drug: oral Diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 75 mg tablet BID (twice a day)
Trial: NCT01046032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
Trial: NCT01287520
Drug: LY2090314
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT02675790
Drug: Moderate Dose Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.
Trial: NCT02675790
Drug: Low Dose Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
Trial: NCT04482595
Drug: BIO 300 Oral Suspension
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension of genistein nanoparticles
Trial: NCT04482595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo for BIO 300 Oral Suspension
Trial: NCT03432884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Placebo
Trial: NCT03802565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03430661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution
Trial: NCT00672841
Drug: Empiric antifungal therapy based on physician discretion.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the standard care group may receive antifungal prophylaxis and/or treatment at any time based on the discretion of the treating physician.
Trial: NCT04779606
Drug: Ocular gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 drops instilled in the right eye
Trial: NCT03938649
Drug: SBRT
RxNorm normalized name: Stereotactic Body Radiation Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
Trial: NCT02624388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill that contains no medicine
Trial: NCT00875433
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients to receive continuous oral daily dosing of BIBW 2992
Trial: NCT00790127
Drug: HQK-1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days
Trial: NCT00790127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules administered once a day, orally, for 56 days
Trial: NCT01167049
Drug: CAPECITABINE
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);
Trial: NCT00637806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension, 5 mL once daily
Trial: NCT00561470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
Trial: NCT01991821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00568087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take oral placebo (identical matching placebo) during the study period.
Trial: NCT01682928
Drug: IV/Oral Hydration and Bedrest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs
Trial: NCT02402270
Drug: NuLYTELY® (PEG 3350)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02402270
Drug: ECP-019
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02402270
Drug: MoviPrep® (PEG 3350)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00561470
Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours